Phase I Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours

Trial Profile

Phase I Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs L19 TNF fusion protein (Primary) ; Doxorubicin
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Philogen
  • Most Recent Events

    • 14 Nov 2016 Planned End Date changed from 1 Feb 2016 to 1 Jun 2018.
    • 14 Nov 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Jun 2018.
    • 07 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top